Sein métastatique HER2+ HER2CLIMB02 (SGNTUC-016) A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer Paris